NCT01834885View on ClinicalTrials.gov

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

QVA149

QVA149 via inhaler twice a day

DRUG

fluticasone/salmeterol

fluticasone/slameterol via inhaler twice a day

Trial Locations (29)

4020

Novartis Investigative Site, Linz

4600

Novartis Investigative Site, Thalheim bei Wels

Novartis Investigative Site, Wels

4710

Novartis Investigative Site, Grieskirchen

5400

Novartis Investigative Site, Hallein

6800

Novartis Investigative Site, Feldkirch

10117

Novartis Investigative Site, Berlin

10119

Novartis Investigative Site, Berlin

10717

Novartis Investigative Site, Berlin

10789

Novartis Investigative Site, Berlin

12203

Novartis Investigative Site, Berlin

12687

Novartis Investigative Site, Berlin

13156

Novartis Investigative Site, Berlin

14467

Novartis Investigative Site, Potsdam

20253

Novartis Investigative Site, Hamburg

20354

Novartis Investigative Site, Hamburg

22335

Novartis Investigative Site, Hamburg

22947

Novartis Investigative Site, Großhansdorf

23552

Novartis Investigative Site, Lübeck

30317

Novartis Investigative Site, Hanover

48145

Novartis Investigative Site, Münster

48431

Novartis Investigative Site, Rheine

60389

Novartis Investigative Site, Frankfurt

60596

Novartis Investigative Site, Frankfurt

63739

Novartis Investigative Site, Aschaffenburg

86825

Novartis Investigative Site, Bad Wörishofen

01307

Novartis Investigative Site, Dresden

04207

Novartis Investigative Site, Leipzig

04357

Novartis Investigative Site, Leipzig

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

All Listed Sponsors

lead

Novartis Pharmaceuticals

INDUSTRY